Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period/Date: July 21, 2017
Context: This filing announces a regulatory submission to the European Medicines Agency (EMA) by GSK and its partner Innoviva, Inc. The submission seeks an extended indication for the respiratory drug Relvar Ellipta (fluticasone furoate/vilanterol) in Europe. The proposed expansion would allow the drug to be used in patients with asthma who are already adequately controlled on an inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) combination, in addition to its current indication for patients not adequately controlled on such therapy.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for any financial metrics. This document is a current report regarding a regulatory event and does not contain financial statements, earnings data, or balance sheet information.
Material Changes Versus Prior Period
Regulatory Status: The material change is the submission of a new indication request to the EMA. Previously, Relvar Ellipta was indicated in Europe for patients aged 12 and over with asthma who were not adequately controlled on both ICS and short-acting beta-agonists (SABA). The new submission targets patients already well-controlled on ICS/LABA combinations.
Clinical Data: The submission relies on positive data from a previously reported non-inferiority lung function study (Study 201378). The study concluded that patients with well-controlled asthma could switch from twice-daily Seretide Accuhaler (fluticasone propionate/salmeterol) to once-daily Relvar Ellipta without compromising lung function. No new safety signals were identified.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Management Commentary: GSK and Innoviva aim to expand the market for Relvar Ellipta by capturing patients currently stable on competitor or legacy therapies. The companies highlight the convenience of a once-daily regimen compared to twice-daily alternatives.
Risks and Contingencies:
- Regulatory Risk: Approval of the extended indication by the EMA is not guaranteed.
- Safety Risks: The filing details significant safety warnings for Relvar Ellipta (and its US counterpart Breo Ellipta), including:
- Increased risk of asthma-related death and hospitalization associated with long-acting beta-agonists (LABAs).
- Increased incidence of pneumonia, particularly in COPD patients (some fatal) and at higher doses in asthma patients.
- Systemic corticosteroid effects (e.g., adrenal suppression, decreased bone mineral density, cataracts).
- Cardiovascular effects (e.g., arrhythmias) and paradoxical bronchospasm.
- Forward-Looking Statements: Both GSK and Innoviva include standard disclaimers that actual results may differ materially from projections due to risks described in their respective Annual Reports (Form 20-F for GSK; Form 10-K/10-Q for Innoviva).
Investor Verification Checklist
- Verify the status of the EMA review for the extended Relvar Ellipta indication and the timeline for a decision.
- Review the full text of the non-inferiority study (201378) referenced in the filing to assess the robustness of the data supporting the switch from Seretide Accuhaler.
- Monitor regulatory communications regarding the safety profile of LABA-containing products, specifically concerning asthma-related mortality and pneumonia risks.
- Check Innoviva's royalty agreement terms with GSK to understand the financial impact of expanded Relvar Ellipta sales on Innoviva's revenue.
- Review GSK's Form 20-F for 2016 and Innoviva's Form 10-Q for Q2 2017 for detailed risk factors and financial context not present in this 6-K.